Clinical trial · Observational
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myelofibrosis | Primary Myelofibrosis | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Participants Undergoing Chart Review
- description
- Participants treated for myelofibrosis undergoing chart review.
Primary outcomes (4)
- measure
- Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment
- timeFrame
- Up to Week 156
- description
- Time from diagnosis of MF to initial treatment.
- measure
- Duration of Initial Treatment
- timeFrame
- Up to Week 156
- description
- Duration of initial treatment.
- measure
- Duration of Second Treatment
- timeFrame
- Up to Week 156
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Treated for myelofibrosis (MF) \[primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)\]. * Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021. Exclusion Criteria: \- Having received MF treatment in a clinical trial setting.
References
Publications (1)
- DERIVEDGupta V, Tomuleasa C, Barranco Lampon GI, Hou HA, Helbig G, Vachhani P, Symeonidis A, Haznedaroglu I, Galvez K, Tatsch F, Chopra AS, Zhang M, Vizkelety T, Murray B, Ross DM. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study. Blood Adv. 2025 Mar 11;9(5):1105-1116. doi: 10.1182/bloodadvances.2024014625. PMID 39729499